[144] Ascendis Pharma A/S American SEC Filing
Insider notice of proposed sale under Rule 144 for Ascendis Pharma A/S (ASND). The filing shows 5,000 American Depositary Shares acquired via warrant exercise and to be sold through Merrill Lynch on NASDAQ with an aggregate market value of $965,000. The filer previously sold 9,375 ADS for $1,826,403.05 earlier in August. The filing discloses the acquisition method (warrant exercise), the broker, the number of shares outstanding (60,454,589) and that payment for the exercised ADS was in cash. The signer also represents they have no undisclosed material adverse information about the issuer.
Avviso di insider relativo a una proposta di vendita ai sensi della Regola 144 per Ascendis Pharma A/S (ASND). La comunicazione segnala la vendita di 5.000 American Depositary Shares acquistate tramite esercizio di warrant, che saranno vendute tramite Merrill Lynch sul NASDAQ per un valore complessivo di $965.000. Il dichiarante aveva precedentemente venduto 9.375 ADS per $1.826.403,05 all'inizio di agosto. La segnalazione indica il metodo di acquisizione (esercizio di warrant), il broker, il numero di azioni in circolazione (60.454.589) e che il pagamento per le ADS esercitate 猫 avvenuto in contanti. Il firmatario dichiara inoltre di non possedere informazioni negative rilevanti non divulgate sull'emittente.
Aviso de insider sobre propuesta de venta conforme a la Regla 144 para Ascendis Pharma A/S (ASND). El documento muestra 5.000 American Depositary Shares adquiridas mediante ejercicio de warrants y que se vender谩n a trav茅s de Merrill Lynch en NASDAQ por un valor agregado de $965.000. El declarante vendi贸 previamente 9.375 ADS por $1.826.403,05 a principios de agosto. La presentaci贸n revela el m茅todo de adquisici贸n (ejercicio de warrants), el corredor, el n煤mero de acciones en circulaci贸n (60.454.589) y que el pago de las ADS ejercitadas fue en efectivo. El firmante tambi茅n declara no tener informaci贸n adversa material no divulgada sobre el emisor.
Ascendis Pharma A/S (ASND)鞐� 雽�頃� 攴滌箼 144鞐� 霐半ジ 毵る弰 鞓堨爼 雮措秬鞛� 韱奠. 鞁犼碃靹涤棎电� 鞗岆煱韸� 頄夓偓搿� 旆摑頃� 5,000臧滌潣 American Depositary Shares臧� Merrill Lynch毳� 韱淀暣 NASDAQ鞐愳劀 齑� $965,000鞐� 毵り皝霅� 鞓堨爼鞚措澕瓿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃鞛愲姅 8鞗� 齑堨棎 鞚措 9,375 ADS毳� $1,826,403.05鞐� 毵る弰頃� 氚� 鞛堨姷雼堧嫟. 鞁犼碃靹涤棎电� 旆摑 氚╇矔(鞗岆煱韸� 頄夓偓), 欷戧皽鞚�, 氚滍枆欤检嫕靾�(60,454,589) 氚� 頄夓偓霅� ADS鞚� 雽�旮堨澊 順勱笀鞙茧 歆�旮夒悩鞐堨潓鞚� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 靹滊獏鞛愲姅 霕愴暅 氚滍枆鞛愳棎 甏�頃� 氙戈车臧滊悳 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 歆勳垹頃╇媹雼�.
Avis d'initi茅 concernant une vente propos茅e selon la r猫gle 144 pour Ascendis Pharma A/S (ASND). Le d茅p么t indique 5 000 American Depositary Shares acquises par exercice de warrants et destin茅es 脿 锚tre vendues via Merrill Lynch sur le NASDAQ pour une valeur totale de 965 000 $. Le d茅clarant avait pr茅c茅demment vendu 9 375 ADS pour 1 826 403,05 $ d茅but ao没t. La d茅claration pr茅cise le mode d'acquisition (exercice de warrants), le courtier, le nombre d'actions en circulation (60 454 589) et que le paiement des ADS exerc茅es a 茅t茅 effectu茅 en esp猫ces. Le signataire d茅clare 茅galement ne pas d茅tenir d'informations d茅favorables importantes non divulgu茅es concernant l'茅metteur.
Insider-Mitteilung 眉ber geplanten Verkauf gem盲脽 Rule 144 f眉r Ascendis Pharma A/S (ASND). Die Einreichung weist 5.000 American Depositary Shares aus, die durch 奥补谤谤补苍迟-础耻蝉眉产耻苍驳 erworben wurden und 眉ber Merrill Lynch an der NASDAQ mit einem Gesamtwert von $965.000 verkauft werden sollen. Der Meldende hatte Anfang August bereits 9.375 ADS f眉r $1.826.403,05 verkauft. Die Meldung nennt die Erwerbsart (奥补谤谤补苍迟-础耻蝉眉产耻苍驳), den Broker, die Anzahl der ausstehenden Aktien (60.454.589) und dass die Zahlung f眉r die ausge眉bten ADS in bar erfolgte. Der Unterzeichner erkl盲rt au脽erdem, keine nicht offengelegten, wesentlichen nachteiligen Informationen 眉ber den Emittenten zu besitzen.
- Disclosure compliance: The filer properly submitted a Rule 144 notice documenting acquisition method, broker, and planned sale.
- Clear acquisition path: Shares were acquired via warrant exercise with cash payment, reducing ambiguity about provenance of securities.
- Insider selling: The filer has executed recent sales (9,375 ADS) and proposes another sale (5,000 ADS), which some investors may view negatively despite immaterial size.
Insights
TL;DR: Small insider sales following a warrant exercise; disclosure aligns with Rule 144 requirements and appears routine.
The 5,000 ADS sale (aggregate value $965k) stems from a warrant exercise and will be brokered by Merrill Lynch on NASDAQ. A prior sale of 9,375 ADS for $1.826M is disclosed for the past three months. Relative to the 60.45 million shares outstanding, these transactions are immaterial on a share-count basis. Primary considerations are compliance with resale rules and potential short-term supply impact. No new operational or financial details about the issuer are provided in this filing.
TL;DR: The filing provides standard Rule 144 transparency; transactions are documented but do not disclose company fundamentals.
The notice documents the source of shares (warrant exercise by Ascendis Pharma A/S) and confirms cash payment on exercise. The filer attests to absence of undisclosed material information, which is a required legal representation. This filing is procedural and governance-focused; it confirms disclosure obligations were met but does not signal corporate governance changes or material events affecting investors.
Avviso di insider relativo a una proposta di vendita ai sensi della Regola 144 per Ascendis Pharma A/S (ASND). La comunicazione segnala la vendita di 5.000 American Depositary Shares acquistate tramite esercizio di warrant, che saranno vendute tramite Merrill Lynch sul NASDAQ per un valore complessivo di $965.000. Il dichiarante aveva precedentemente venduto 9.375 ADS per $1.826.403,05 all'inizio di agosto. La segnalazione indica il metodo di acquisizione (esercizio di warrant), il broker, il numero di azioni in circolazione (60.454.589) e che il pagamento per le ADS esercitate 猫 avvenuto in contanti. Il firmatario dichiara inoltre di non possedere informazioni negative rilevanti non divulgate sull'emittente.
Aviso de insider sobre propuesta de venta conforme a la Regla 144 para Ascendis Pharma A/S (ASND). El documento muestra 5.000 American Depositary Shares adquiridas mediante ejercicio de warrants y que se vender谩n a trav茅s de Merrill Lynch en NASDAQ por un valor agregado de $965.000. El declarante vendi贸 previamente 9.375 ADS por $1.826.403,05 a principios de agosto. La presentaci贸n revela el m茅todo de adquisici贸n (ejercicio de warrants), el corredor, el n煤mero de acciones en circulaci贸n (60.454.589) y que el pago de las ADS ejercitadas fue en efectivo. El firmante tambi茅n declara no tener informaci贸n adversa material no divulgada sobre el emisor.
Ascendis Pharma A/S (ASND)鞐� 雽�頃� 攴滌箼 144鞐� 霐半ジ 毵る弰 鞓堨爼 雮措秬鞛� 韱奠. 鞁犼碃靹涤棎电� 鞗岆煱韸� 頄夓偓搿� 旆摑頃� 5,000臧滌潣 American Depositary Shares臧� Merrill Lynch毳� 韱淀暣 NASDAQ鞐愳劀 齑� $965,000鞐� 毵り皝霅� 鞓堨爼鞚措澕瓿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃鞛愲姅 8鞗� 齑堨棎 鞚措 9,375 ADS毳� $1,826,403.05鞐� 毵る弰頃� 氚� 鞛堨姷雼堧嫟. 鞁犼碃靹涤棎电� 旆摑 氚╇矔(鞗岆煱韸� 頄夓偓), 欷戧皽鞚�, 氚滍枆欤检嫕靾�(60,454,589) 氚� 頄夓偓霅� ADS鞚� 雽�旮堨澊 順勱笀鞙茧 歆�旮夒悩鞐堨潓鞚� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 靹滊獏鞛愲姅 霕愴暅 氚滍枆鞛愳棎 甏�頃� 氙戈车臧滊悳 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 歆勳垹頃╇媹雼�.
Avis d'initi茅 concernant une vente propos茅e selon la r猫gle 144 pour Ascendis Pharma A/S (ASND). Le d茅p么t indique 5 000 American Depositary Shares acquises par exercice de warrants et destin茅es 脿 锚tre vendues via Merrill Lynch sur le NASDAQ pour une valeur totale de 965 000 $. Le d茅clarant avait pr茅c茅demment vendu 9 375 ADS pour 1 826 403,05 $ d茅but ao没t. La d茅claration pr茅cise le mode d'acquisition (exercice de warrants), le courtier, le nombre d'actions en circulation (60 454 589) et que le paiement des ADS exerc茅es a 茅t茅 effectu茅 en esp猫ces. Le signataire d茅clare 茅galement ne pas d茅tenir d'informations d茅favorables importantes non divulgu茅es concernant l'茅metteur.
Insider-Mitteilung 眉ber geplanten Verkauf gem盲脽 Rule 144 f眉r Ascendis Pharma A/S (ASND). Die Einreichung weist 5.000 American Depositary Shares aus, die durch 奥补谤谤补苍迟-础耻蝉眉产耻苍驳 erworben wurden und 眉ber Merrill Lynch an der NASDAQ mit einem Gesamtwert von $965.000 verkauft werden sollen. Der Meldende hatte Anfang August bereits 9.375 ADS f眉r $1.826.403,05 verkauft. Die Meldung nennt die Erwerbsart (奥补谤谤补苍迟-础耻蝉眉产耻苍驳), den Broker, die Anzahl der ausstehenden Aktien (60.454.589) und dass die Zahlung f眉r die ausge眉bten ADS in bar erfolgte. Der Unterzeichner erkl盲rt au脽erdem, keine nicht offengelegten, wesentlichen nachteiligen Informationen 眉ber den Emittenten zu besitzen.
FAQ
What does the Form 144 for Ascendis Pharma (ASND) disclose?
Who is the seller named in the Form 144 for ASND?
How many Ascendis Pharma shares are outstanding according to the filing?
How were the 5,000 ADS acquired?
Does the filing indicate any undisclosed material information about Ascendis Pharma?
